Your browser doesn't support javascript.
loading
GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage.
Pintado-Berninches, Laura; Montes-Worboys, Ana; Manguan-García, Cristina; Arias-Salgado, Elena G; Serrano, Adela; Fernandez-Varas, Beatriz; Guerrero-López, Rosa; Iarriccio, Laura; Planas, Lurdes; Guenechea, Guillermo; Egusquiaguirre, Susana P; Hernandez, Rosa M; Igartua, Manoli; Luis Pedraz, Jose; Cortijo, Julio; Sastre, Leandro; Molina-Molina, Maria; Perona, Rosario.
Affiliation
  • Pintado-Berninches L; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.
  • Montes-Worboys A; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  • Manguan-García C; ILD Unit, Pneumology Department, University Hospital of Bellvitge, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.
  • Arias-Salgado EG; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.
  • Serrano A; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  • Fernandez-Varas B; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.
  • Guerrero-López R; Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain.
  • Iarriccio L; CIBER of Respiratory diseases (CIBERES), Health Institute Carlos III, Madrid, Spain.
  • Planas L; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.
  • Guenechea G; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.
  • Egusquiaguirre SP; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  • Hernandez RM; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.
  • Igartua M; ILD Unit, Pneumology Department, University Hospital of Bellvitge, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.
  • Luis Pedraz J; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  • Cortijo J; Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD/UAM), Madrid, Spain.
  • Sastre L; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), CIBER-BBN, Vitoria-Gasteiz, Spain.
  • Molina-Molina M; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), CIBER-BBN, Vitoria-Gasteiz, Spain.
  • Perona R; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), CIBER-BBN, Vitoria-Gasteiz, Spain.
FASEB J ; 35(3): e21422, 2021 03.
Article in En | MEDLINE | ID: mdl-33638895
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bleomycin / DNA Damage / Apoptosis / Nanoparticles / Lung Type of study: Guideline Limits: Humans Language: En Journal: FASEB J Journal subject: BIOLOGIA / FISIOLOGIA Year: 2021 Document type: Article Affiliation country: España
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bleomycin / DNA Damage / Apoptosis / Nanoparticles / Lung Type of study: Guideline Limits: Humans Language: En Journal: FASEB J Journal subject: BIOLOGIA / FISIOLOGIA Year: 2021 Document type: Article Affiliation country: España